Pyxis Oncology, Inc. (PYXS) Social Stream
PYXIS ONCOLOGY INC (PYXS) Price Targets From Analysts
Use the tables below to see what analysts covering PYXIS ONCOLOGY INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-19 | 4 | $25 | $16 | $22 | $2.42 | 809.09% |
| 2022-03-29 | 4 | $25 | $15 | $20 | $2.42 | 726.45% |
| 2022-04-04 | 4 | $25 | $13 | $19.333 | $2.42 | 698.88% |
| 2022-05-13 | 4 | $21 | $13 | $18 | $2.42 | 643.8% |
| 2022-08-15 | 4 | $21 | $4 | $11.666 | $2.42 | 382.07% |
| 2022-10-07 | 2 | $16 | $4 | $10 | $2.42 | 313.22% |
| 2022-11-11 | 3 | $16 | $4 | $10 | $2.42 | 313.22% |
| 2023-02-08 | 4 | $16 | $4 | $10 | $2.42 | 313.22% |
| 2023-03-27 | 4 | $16 | $4 | $9.666 | $2.42 | 299.42% |
| 2023-05-16 | 4 | $16 | $4 | $9.667 | $2.42 | 299.46% |
| 2023-06-06 | 4 | $13 | $4 | $8.667 | $2.42 | 258.14% |
| 2023-08-14 | 6 | $15 | $4 | $10.25 | $2.42 | 323.55% |
| 2023-09-05 | 6 | $15 | $7 | $11 | $2.42 | 354.55% |
| 2023-09-26 | 6 | $15 | $4 | $9.6 | $2.42 | 296.69% |
| 2023-11-09 | 6 | $15 | $2 | $7.25 | $2.42 | 199.59% |
| 2023-11-30 | 6 | $7 | $2 | $4.5 | $2.42 | 85.95% |
The Trend in the Analyst Price Target
Over the past 16 months, PYXS's average price target has gone down $7.17.
PYXS reports an average of 304.79% for its upside potential over the past 44 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-22 | 4 | 16 | 4 | 9.666 | 2.20 | 339.36% |
| 2023-05-11 | 4 | 16 | 4 | 9.667 | 3.04 | 217.99% |
| 2023-06-06 | 4 | 13 | 4 | 8.667 | 3.23 | 168.33% |
| 2023-11-30 | 6 | 7 | 2 | 4.500 | 1.59 | 183.02% |
| 2023-11-30 | 7 | 15 | 2 | 6.600 | 1.59 | 315.09% |
PYXS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.5 | 4 | 1 | 1 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 153 days, PYXS's average broker recommendation rating worsened by 0.1.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- PYXS has a greater upside potential (average analyst target price relative to current price) than 2093.75% of all US stocks.
- In terms of how PYXIS ONCOLOGY INC fares relative to all US stocks, note that its average analyst price target is higher than 308.39% of that group.
- PYXS has a lower variance in analysts' estimates than -1845.74% of all US stocks.
- PYXS has a greater number of analysts covering the stock than 425.02% of all US stocks.
Stocks similar to PYXIS ONCOLOGY INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are XLO, TRDA, and LIAN.
View All Top Stocks by Price Target
Is PYXS a Buy, Hold or Sell? See the POWR Ratings now!